Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 File Acceptance News

File Acceptance News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from File Acceptance. Real-time updates on events, politics, business and more.

Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara®

November 30, 2023
EQS-News: Formycon AG / Key word(s): Regulatory AdmissionFormycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration 30.11.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press R...
United States Stefan Glombitza Fresenius Kabi Drug Administration Distribution Services Corporate Communications
Source: pharmiweb.com

Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)

August 29, 2023
EQS-News: Formycon AG / Key word: Regulatory Admission/Miscellaneous Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 , by the U.S....
Stefan Glombitza Klinge Biopharma Gmbh Drug Administration Trademark Of Regeneron Pharmaceuticals Inc Corporate Communications Press Release
Source: marketscreener.com

Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by t

August 29, 2023
EQS-News: Formycon AG / Key word(s): Regulatory Admission/MiscellaneousFormycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA) 29.08.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press...
United States Stefan Glombitza Klinge Biopharma Gmbh Corporate Communications Drug Administration Trademark Of Regeneron Pharmaceuticals Inc
Source: pharmiweb.com

Investegate |Formycon AG Announcements | Formycon AG: Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)

October 1, 2021
Investegate announcements from Formycon AG, Formycon and Bioeq announce File Acceptance for FYB201, a biosimilar candidate to Lucentis(R) (ranibizumab) by the U.S. Food and Drug Administration (FDA)
United States Polpharma Biologics Group Corporate Communications Coherus Biosciences Inc Drug Administration Genentech Inc
Source: investegate.co.uk

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science